All Stories

  1. Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling

    Article • Antimicrobial Agents and Chemotherapy, February 2023, ASM Journals

    DR Maxwell Tawanda Chirehwa

  2. Pharmacokinetics and Dose Optimization Strategies of Para-Aminosalicylic Acid in Children with Rifampicin-Resistant Tuberculosis

    Article • Antimicrobial Agents and Chemotherapy, June 2022, ASM Journals

    DR Maxwell Tawanda Chirehwa

  3. Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis

    Article • Journal of Antimicrobial Chemotherapy, June 2022, Oxford University Press (OUP)

    DR Maxwell Tawanda Chirehwa

  4. Effect of Isoniazid Intake on Ethionamide Pharmacokinetics and Target Attainment in Multidrug-Resistant Tuberculosis Patients

    Article • Antimicrobial Agents and Chemotherapy, September 2021, ASM Journals

    DR Maxwell Tawanda Chirehwa

  5. Pharmacokinetics of First-Line Drugs in Children With Tuberculosis, Using World Health Organization–Recommended Weight Band Doses and Formulations

    Article • Clinical Infectious Diseases, August 2021, Oxford University Press (OUP)

    DR Maxwell Tawanda Chirehwa

  6. Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis

    Article • International Journal of Infectious Diseases, April 2021, Elsevier

    DR Maxwell Tawanda Chirehwa

  7. Population Pharmacokinetics of Cycloserine and Pharmacokinetic/Pharmacodynamic Target Attainment in Multidrug-Resistant Tuberculosis Patients Dosed with Terizidone

    Article • Antimicrobial Agents and Chemotherapy, October 2020, ASM Journals

    DR Maxwell Tawanda Chirehwa

  8. Early antituberculosis drug exposure in hospitalized patients with human immunodeficiency virus associated tuberculosis

    Article • British Journal of Clinical Pharmacology, January 2020, Wiley

    DR Maxwell Tawanda Chirehwa

  9. Pharmacokinetics and other risk factors for kanamycin-induced hearing loss in patients with multi-drug resistant tuberculosis

    Article • International Journal of Audiology, November 2019, Taylor & Francis

    DR Maxwell Tawanda Chirehwa, Mrs Lucretia Petersen

  10. Effect of tablet crushing on drug exposure in the treatment of multidrug-resistant tuberculosis

    Article • The International Journal of Tuberculosis and Lung Disease, October 2019, International Union Against Tuberculosis and Lung Disease

    DR Maxwell Tawanda Chirehwa

  11. Value of the Goodenough Drawing Test as a research tool to detect developmental delay in South African preschool children

    Article • South African Journal of Psychology, June 2019, SAGE Publications

    DR Maxwell Tawanda Chirehwa

  12. Quantitative assessment of the activity of antituberculosis drugs and regimens

    Article • Expert Review of Anti-infective Therapy, May 2019, Taylor & Francis

    Gustavo Velásquez, Dr Tawanda Gumbo, DR Maxwell Tawanda Chirehwa

  13. Propagation of measurement errors in glomerular filtration rate determination

    Article • Nuclear Medicine Communications, April 2019, Wolters Kluwer Health

    DR Maxwell Tawanda Chirehwa

  14. Low Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?

    Article • Antimicrobial Agents and Chemotherapy, March 2019, ASM Journals

    DR Maxwell Tawanda Chirehwa

  15. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis

    Article • Pharmacogenomics, March 2019, Future Medicine

    DR Maxwell Tawanda Chirehwa

  16. Current research toward optimizing dosing of first-line antituberculosis treatment

    Article • Expert Review of Anti-infective Therapy, December 2018, Taylor & Francis

    DR Maxwell Tawanda Chirehwa

  17. Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid

    Article • Journal of Antimicrobial Chemotherapy, September 2018, Oxford University Press (OUP)

    DR Maxwell Tawanda Chirehwa

  18. Effect of lidocaine on kanamycin injection-site pain in patients with multidrug-resistant tuberculosis

    Article • The International Journal of Tuberculosis and Lung Disease, August 2018, International Union Against Tuberculosis and Lung Disease

    DR Maxwell Tawanda Chirehwa

  19. Assessment of quality of obstetric care in Zimbabwe using the standard primipara

    Article • BMC Pregnancy and Childbirth, June 2018, Springer Science + Business Media

    DR Maxwell Tawanda Chirehwa

  20. Quality of pilot trial abstracts in heart failure is suboptimal: a systematic survey

    Article • Pilot and Feasibility Studies, May 2018, Springer Science + Business Media

    DR Maxwell Tawanda Chirehwa

  21. Evaluation of the Effectiveness of Dose Individualization to Achieve Therapeutic Vancomycin Concentrations

    Article • The Journal of Clinical Pharmacology, May 2018, Wiley

    DR Maxwell Tawanda Chirehwa

  22. Quality assurance of rifampicin-containing fixed-drug combinations in South Africa: dosing implications

    Article • The International Journal of Tuberculosis and Lung Disease, May 2018, International Union Against Tuberculosis and Lung Disease

    DR Maxwell Tawanda Chirehwa

  23. OUP accepted manuscript

    Article • Journal of Tropical Pediatrics, January 2018, Oxford University Press (OUP)

    DR Maxwell Tawanda Chirehwa

  24. Effect of genetic variation in UGT1A and ABCB1 on moxifloxacin pharmacokinetics in South African patients with tuberculosis

    Article • Pharmacogenomics, December 2017, Future Medicine

    DR Maxwell Tawanda Chirehwa

  25. Quality of abstracts of pilot trials in heart failure: A protocol for a systematic survey

    Article • Contemporary Clinical Trials Communications, December 2017, Elsevier

    DR Maxwell Tawanda Chirehwa

  26. Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis

    Article • Antimicrobial Agents and Chemotherapy, June 2017, ASM Journals

    DR Maxwell Tawanda Chirehwa

  27. Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB

    Article • Journal of Antimicrobial Chemotherapy, February 2017, Oxford University Press (OUP)

    Professor Sabiha Yusuf Essack, DR Maxwell Tawanda Chirehwa

  28. Use of the ‘Accountability for Reasonableness’ Approach to Improve Fairness in Accessing Dialysis in a Middle-Income Country

    Article • PLOS One, October 2016, PLOS

    DR Maxwell Tawanda Chirehwa

  29. HIV-1 Coinfection Does Not Reduce Exposure to Rifampin, Isoniazid, and Pyrazinamide in South African Tuberculosis Outpatients

    Article • Antimicrobial Agents and Chemotherapy, August 2016, ASM Journals

    DR Maxwell Tawanda Chirehwa

  30. Model-Based Evaluation of Higher Doses of Rifampin Using a Semimechanistic Model Incorporating Autoinduction and Saturation of Hepatic Extraction

    Article • Antimicrobial Agents and Chemotherapy, November 2015, ASM Journals

    DR Maxwell Tawanda Chirehwa

  31. Impact of Xpert MTB/RIF on Antiretroviral Therapy-Associated Tuberculosis and Mortality: A Pragmatic Randomized Controlled Trial

    Article • Open Forum Infectious Diseases, January 2014, Oxford University Press (OUP)

    DR Maxwell Tawanda Chirehwa

  32. Elective reconstruction of the ascending aorta for aneurysmal disease restores normal life expectancy. An analysis of risk factors for early and late mortality

    Article • Acta Cardiologica, August 2013, Taylor & Francis

    DR Maxwell Tawanda Chirehwa

  33. Renal abnormalities among HIV-infected, antiretroviral naive children, Harare, Zimbabwe: a cross-sectional study

    Article • BMC Pediatrics, May 2013, Springer Science + Business Media

    DR Maxwell Tawanda Chirehwa

  34. Consequences of polyparasitism on anaemia among primary school children in Zimbabwe

    Article • Acta Tropica, July 2010, Elsevier

    DR Maxwell Tawanda Chirehwa

  35. O559 Causes of perinatal mortality: Results from a population-based national study in Zimbabwe

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    DR Maxwell Tawanda Chirehwa

  36. O646 The maternal mortality ratio of Zimbabwe in 2007

    Article • International Journal of Gynecology & Obstetrics, October 2009, Wiley

    DR Maxwell Tawanda Chirehwa